GlassScriptPhysician profile
Elnore Herring Cushnie
NPI 1306596309
$7,881.35
in general payments reported to CMS, 2019-2025
16 companies · $2,873 in 2025
The $2,873 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,193 · 2023: $1,592 · 2024: $2,224 · 2025: $2,873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,522 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,522.37 |
| Education | $166.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,094.33 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,462.93 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $1,437.42 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $687.87 | 2022-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Janssen Pharmaceuticals, INC | $630.12 | 2022-2024 | Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $428.61 | 2022-2025 | Lybalvi, Aristada, Vivitrol |
| Vanda Pharmaceuticals INC. | $258.47 | 2022-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $243.95 | 2022-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $234.10 | 2023-2025 | Auvelity |
| Avanir Pharmaceuticals, INC. | $116.40 | 2022 | |
| Indivior INC. | $111.05 | 2022-2023 | Perseris |
| Sunovion Pharmaceuticals INC. | $57.02 | 2022 | |
| Lundbeck LLC | $53.02 | 2023 | Rexulti |
| Idorsia Pharmaceuticals US INC | $34.38 | 2022-2023 | Quviviq |
| Luye Pharma (USA) LTD. | $17.76 | 2025 | Erzofri Extended-Release |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $13.92 | 2025 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elnore Cushnie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.